美國(guó)Alfa 瘦肉精監(jiān)測(cè)卡

廣州健侖生物科技有限公司

我司長(zhǎng)期供應(yīng)瘦肉精三聯(lián)檢測(cè)卡，本產(chǎn)品用于快速檢測(cè)動(dòng)物尿樣、組織和飼料中鹽酸克倫特羅、萊克多巴胺、沙丁胺醇殘留，整個(gè)檢測(cè)過(guò)程只需要3-5分鐘左右，具有操作簡(jiǎn)單，方便快捷，靈敏度高特異性強(qiáng)等特點(diǎn)。

瘦肉精檢測(cè)試劑進(jìn)口品牌：美國(guó)Alfa、美國(guó)US

我司還提供其它進(jìn)口或國(guó)產(chǎn)試劑盒：登革熱、瘧疾、流感、A鏈球菌、合胞病毒、腮病毒、乙腦、寨卡、黃熱病、基孔肯雅熱、克錐蟲病、違禁品濫用、肺炎球菌、軍團(tuán)菌、化妝品檢測(cè)、食品安全檢測(cè)等試劑盒以及日本生研細(xì)菌分型診斷血清、德國(guó)SiFin診斷血清、丹麥SSI診斷血清等產(chǎn)品。

歡迎咨詢

歡迎咨詢

瘦肉精檢測(cè)試劑盒、瘦肉精檢測(cè)試劑、瘦肉精檢測(cè)卡、瘦肉精檢測(cè)試紙、瘦肉精快速檢測(cè)卡、瘦肉精三聯(lián)檢測(cè)卡、鹽酸克倫特羅檢測(cè)卡、萊克多巴胺檢測(cè)卡、沙丁胺醇檢測(cè)卡

【瘦肉精的危害】

“瘦肉精”進(jìn)入動(dòng)物體內(nèi)后主要分布于肝臟。肌肉中含量較肝臟低很多。人攝入后在體內(nèi)存留時(shí)間較長(zhǎng)，其不良反應(yīng)主要有：可引起心率加速，特別是原有心律失常的病例更易發(fā)生心臟反應(yīng)，可見心室早搏、ST段與T波幅壓低，還會(huì)發(fā)出肌肉震顫，引發(fā)四肢、面頸部骨骼肌震顫，尤其是交感神經(jīng)功能亢進(jìn)的病例更易發(fā)生。此外，還可引起代謝紊亂、血鉀降低，引起心慌、肌肉震顫、頭痛以及臉部潮紅等。對(duì)心率失常、高血壓、青光眼、糖尿病、甲狀腺機(jī)能亢進(jìn)等疾病的患者有較大危害。

美國(guó)Alfa 瘦肉精監(jiān)測(cè)卡

【產(chǎn)品簡(jiǎn)介】

本產(chǎn)品為克倫特羅-萊克多巴胺-沙丁胺醇三合一膠體金快速檢測(cè)卡，用于定性檢測(cè)豬、牛、羊尿液、組織和飼料中的瘦肉精殘留，整個(gè)檢測(cè)過(guò)程只需要3-5分鐘左右。

【檢測(cè)限】

克倫特羅3ng/ml（3ppb），萊克多巴胺3ng/ml（3ppb），沙丁胺醇3ng/ml（3ppb）

【產(chǎn)品組成】

克倫特羅-萊克多巴胺-沙丁胺醇三合一膠體金快速檢測(cè)卡（40T/盒）

滴管（1個(gè)/袋）、干燥劑（1片/袋）

【樣品處理】

用干燥、潔凈的離心管或適當(dāng)容器采集50ml左右尿液。如果不立即檢測(cè)，待檢樣本在2-8℃存放，可保存24小時(shí)，注意避免腐壞造成失效或污染。出現(xiàn)陽(yáng)性結(jié)果應(yīng)按法定程序分瓶封裝樣品用于確證法檢測(cè)。

【使用步驟】

1、測(cè)試前先完整閱讀說(shuō)明書，使用前將檢測(cè)卡和待檢樣本溶液恢復(fù)至室溫4～30℃。

2、從原包裝袋中取出檢測(cè)卡，打開后請(qǐng)?jiān)谝粋€(gè)小時(shí)內(nèi)盡快地使用。

3、將檢測(cè)卡平放，用滴管吸取待檢樣品溶液，緩慢垂直滴加2-3滴于加樣孔中，加樣后開始計(jì)時(shí)。

4、結(jié)果應(yīng)在3-5分鐘時(shí)讀取，其他時(shí)間判讀無(wú)效，根據(jù)示意圖判定結(jié)果。

【結(jié)果判斷】

1. 陰性（-）：兩條紫紅色條帶出現(xiàn)。表示樣品中不含有瘦肉精或其濃度低于檢測(cè)限。
2. 陽(yáng)性（+）：檢測(cè)T線無(wú)顯色，則表示樣品中瘦肉精濃度高于檢測(cè)限。

1. 無(wú)效：未出現(xiàn)質(zhì)控C線，表明操作過(guò)程不正確或檢測(cè)卡已失效。

【注意事項(xiàng)】

1、檢測(cè)卡請(qǐng)?jiān)诒Ｙ|(zhì)期內(nèi)一次性使用；

2、檢測(cè)時(shí)避免陽(yáng)光直射和電風(fēng)扇直吹；

3、盡量不要觸摸檢測(cè)卡中央的白色膜面；

4、采樣滴管不可混用，以免交叉污染；

5、如果待檢樣本出現(xiàn)沉淀或渾濁物，請(qǐng)離心后再檢測(cè)；

6、試驗(yàn)遇到的任何問(wèn)題，請(qǐng)與供應(yīng)商。

【儲(chǔ)存及有效期】

原包裝應(yīng)儲(chǔ)存于4～40℃，陰涼避光干燥處，切勿冷凍；有效期24個(gè)月。有效期及批號(hào)見外包裝。

美國(guó)Alfa

2009年，隨著醫(yī)藥行業(yè)專項(xiàng)整治可能帶來(lái)的市場(chǎng)規(guī)范化程度提升、新醫(yī)改方案帶來(lái)市場(chǎng)擴(kuò)容機(jī)會(huì)、新上市產(chǎn)品的增加、藥品終端需求活躍以及新一輪投資熱潮等眾多有利因素將保證中國(guó)醫(yī)藥行業(yè)繼續(xù)快速增長(zhǎng)。但隨著金融危機(jī)的蔓延和世界經(jīng)濟(jì)的減速，中國(guó)醫(yī)藥外貿(mào)面臨的形勢(shì)更加嚴(yán)峻。2009年有可能是進(jìn)入新世紀(jì)以來(lái)zui為困難的一年。但是由于中國(guó)醫(yī)藥行業(yè)的特點(diǎn)以及新醫(yī)改對(duì)內(nèi)需的拉動(dòng)作用，中國(guó)醫(yī)藥進(jìn)出口總額有望繼續(xù)保持一定的增長(zhǎng)。“變壓力為動(dòng)力、化挑戰(zhàn)為機(jī)遇”將成為2009年中國(guó)醫(yī)藥外貿(mào)發(fā)展的主旋律。
藥水
藥水
展望未來(lái)，中國(guó)醫(yī)藥行業(yè)景氣才剛剛開始，未來(lái)提升空間巨大。醫(yī)藥產(chǎn)業(yè)進(jìn)入新醫(yī)改牽引下的新一輪有序發(fā)展期。未來(lái)新醫(yī)改方案將對(duì)中國(guó)醫(yī)藥行業(yè)的市場(chǎng)結(jié)構(gòu)、產(chǎn)業(yè)結(jié)構(gòu)、產(chǎn)品結(jié)構(gòu)等方面產(chǎn)生深刻的影響，到2010年，醫(yī)改帶來(lái)的藥品增量至少在1000億以上，加上行業(yè)自然增長(zhǎng)部分，預(yù)計(jì)未來(lái)3-5年醫(yī)藥行業(yè)的年增長(zhǎng)率不會(huì)低于20%。
中藥情景
整個(gè)中藥材產(chǎn)需及市場(chǎng)供求關(guān)系將發(fā)生以下變化：
1、生產(chǎn)相對(duì)穩(wěn)定，貨源緊中有松。隨著我國(guó)農(nóng)村產(chǎn)業(yè)結(jié)構(gòu)初見成效，糧棉總量調(diào)減，優(yōu)質(zhì)品種增加，市價(jià)略有回升，各種經(jīng)濟(jì)作物亦按照市場(chǎng)需求進(jìn)行調(diào)整，作為農(nóng)付產(chǎn)品的中藥材，自1997年下半年出現(xiàn)總體減少，價(jià)格一路下滑，至今已持續(xù)三年多,由于藥價(jià)偏低，藥材生產(chǎn)大多微利或低于生產(chǎn)成本，使藥農(nóng)的種植積極性大打折扣。同時(shí)藥農(nóng)痛定思痛，吸取教訓(xùn)，開始面向市場(chǎng)有的放失發(fā)展生產(chǎn)，壓縮那些滯銷積壓的品種面積，擴(kuò)大市場(chǎng)緊俏*的品種生產(chǎn)面積，經(jīng)過(guò)幾年的市場(chǎng)調(diào)節(jié)與生產(chǎn)調(diào)整，藥材市場(chǎng)的供求關(guān)系開始趨向合理，據(jù)有關(guān)資料顯示，近一二年全國(guó)家種面積一直保持在37-40萬(wàn)公頃之間波動(dòng)，尤其山東、江蘇、陜西、云南、貴州、安徽、山西等省份發(fā)展迅猛。預(yù)計(jì)年內(nèi)常用大宗品種，如桔梗、板蘭根、生地黃、白芷、牛膝、玄參、白藥、太子參、紅花、川芎、黨參、北沙參等品種因受前幾年市場(chǎng)“高炒”價(jià)格跌至近幾年來(lái)的谷底的影響，生產(chǎn)出現(xiàn)不同程度的違禁品，市場(chǎng)行情正處于由低向高運(yùn)行的轉(zhuǎn)折點(diǎn)，隨著歷年庫(kù)存的消耗，這些品種價(jià)格可望發(fā)生逆轉(zhuǎn)。少部分多年生品種如山茱萸、黃連等品種因多種因素影響,供求矛盾尚難好轉(zhuǎn),貨源將日益緊缺。大茴、小良姜、山萘、丁香、草果等藥食兼用的香料藥材品種，因其價(jià)格偏高，按市場(chǎng)規(guī)律 。

美國(guó)Alfa

我司還提供其它進(jìn)口或國(guó)產(chǎn)試劑盒：登革熱、瘧疾、流感、A鏈球菌、合胞病毒、腮病毒、乙腦、寨卡、黃熱病、基孔肯雅熱、克錐蟲病、違禁品濫用、肺炎球菌、軍團(tuán)菌、食品安全、化妝品檢測(cè)、藥物濫用檢測(cè)等試劑盒以及日本生研細(xì)菌分型診斷血清、德國(guó)SiFin診斷血清、丹麥SSI診斷血清等產(chǎn)品。

想了解更多的產(chǎn)品及服務(wù)請(qǐng)掃描下方二維碼：

【公司名稱】 廣州健侖生物科技有限公司
【市場(chǎng)部】    楊永漢

【】 
【騰訊  】 
【公司地址】 廣州清華科技園創(chuàng)新基地番禺石樓鎮(zhèn)創(chuàng)啟路63號(hào)二期2幢101-103室

In 2009, with the standardization of the market brought by special rectification by the pharmaceutical industry, the new healthcare reform program will bring about opportunities for expansion of the market. The favorable factors such as the increase of new listings, the active demand of pharmaceutical terminals and the new round of investment boom will ensure that China The pharmaceutical industry continues to grow rapidly. However, with the spread of the financial crisis and the slowdown of the world economy, the situation facing China's pharmaceutical foreign trade is even more severe. 2009 may be the most difficult year since entering the new century. However, due to the characteristics of China's pharmaceutical industry and the stimulating effect of the new medical reform on domestic demand, the total volume of China's pharmaceutical exports and imports is expected to continue to grow at a certain rate. "Transforming pressure into motivation and turning challenges into opportunities" will become the main theme of the development of China's pharmaceutical foreign trade in 2009.
Potion
Potion
Looking to the future, the prosperity of China's pharmaceutical industry has just begun, huge room for improvement in the future. The pharmaceutical industry has entered a new round of orderly development under the guidance of new medical reform. The new medical reform plan in the future will have a profound impact on the market structure, industrial structure and product structure of China's pharmaceutical industry. By 2010, the increase in pharmaceuticals brought by medical reform will be at least 100 billion or more. Coupled with the natural growth of the industry, The next three to five years the pharmaceutical industry will not be less than 20% annual growth rate.
Chinese scene
The entire Chinese herbal medicine production and demand and market supply and demand will occur the following changes:
1, the production is relatively stable, tight supply tight. With the initial success of China's rural industrial structure, the total amount of grain and cotton decreased, the quality of varieties increased, the market price rebounded slightly, and various cash crops were also adjusted according to market demand. As the traditional Chinese medicines for agricultural products, since the second half of 1997 As a whole, the prices have been decreasing and the price has been falling all the way. It has lasted for more than three years. Due to the low price of medicines, the production of medicinal herbs is mostly at a low profit or below the production cost, which greatly reduces the enthusiasm of the farmers. At the same time, medicine and agricultural science and thinking pain, learn a lesson, some market-oriented start to lose the development of production, compression of those who sell off the backlog of varieties of area, expanding the market tight and profitable production area, after years of market regulation and production adjustment, medicine market supply and demand The trend is reasonable. According to relevant statistics, the total area of ??family-owned species in the country has fluctuated between 3,700,000 and 4,000 hectares in recent one or two years. In particular, the provinces of Shandong, Jiangsu, Shaanxi, Yunnan, Guizhou, Anhui and Shanxi have been developing rapidly. It is estimated that the varieties commonly used during the year such as Campanulaceae, Radix, Radix Rehmanniae, Angelica, Achyranthes, Scrophulariaceae, Baiyao, heterophylla, safflower, Chuanxiong, Codonopsis, Pak Sanshen varieties due to the market a few years ago, "speculation" price Fell to the bottom in recent years, the impact of the production of varying degrees of contraband, the market is at a turning point from low to high, with the depletion of inventory over the years, these varieties are expected to reverse the price. A small number of perennial varieties such as dogwood, berberine and other varieties due to many factors, the supply and demand is still difficult to improve the contradiction between supply will increasingly scarce. Fennel, small galangal, naphthalene, cloves, grass and other medicinal herbs and spices spices, because of their high prices, according to market rules.